BIOXYTRAN, INC
BIXT
A
|
$0.1309
-10.34%
490.75%
240K
|
Professional, Scientific, and T...
(0.0% 1d) (24.8% 1m) (-72.9% 1y) (0.0% 2d) (-13.3% 3d) (0.0% 7d) (96.95% volume)
Earnings Calendar:
Market Cap: $ 22,774,247
https://www.bioxytraninc.com/
Sec Filling | Patents | 3 employees
(US) bioxytran, inc., an early stage pharmaceutical company, focuses on the development, manufacture, and commercialization of various therapeutic drugs to address hypoxia in humans. the company's lead pharmaceutical drug candidate is bxt-25, an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer for the treatment of patients with ischemia of the brain resulting from a stroke or the blockage of the blood vessels to the brain. its products also include bxt-252, an injectable anti-necrosis drug to treat a wound that does not heal because limited amount of oxygen reaching the wound. the company was founded in 2017 and is headquartered in newton, massachusetts.
injection
add to watch list Paper trade email alert is off
Your Today's Watch List
Sign in to create a watchlistGainers vs Losers
| 61% | 39% |
Top 10 Gainers
CSSE 4 | $0.4253 179.25% 64.77% 210M
|
Consumer Services
BOF | $2.08 77.78% 41.21% 110M
|
ILAG | $0.54 12.27% 40.62% 3.7M
|
LICN | $0.999 78.39% 40.49% 15M
|
AMST | $3.4 70.0% 39.58% 70M
|
Technology Services
MTC | $3.6 60.71% 38.04% 9.1M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.458 14.5% 30.92% 91K
|
Health Services
WHLM | $6.25 35.87% 28.46% 700K
|
Commercial Services
MULN | News | $3.77 38.1% 27.78% 13M
|
Information
Last 48 Hours Insiders Buying
RKT P 347 | $12.55 -0.63% 1.12% 1.5M
|
Finance
|
22:30
NWFL | News | $24.21 0.42% 1.99% 9.9K
|
Finance
|
22:00
TGEN P 10000 | $0.68 -0.73% 39.71% 20K
|
Utilities
|
20:01
MNSB P 310 | $15.89 -2.87% -3.02% 46K
|
Finance
|
15:30
RMCF | $3.55 0.28% 0.28% 7.1K
|
Consumer Non-Durables
|
20:10